Comparison · NCT02367040-deaths
Copanlisib + Rituximab vs Placebo + Rituximab: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Copanlisib + Rituximab vs Placebo + Rituximab: deaths from any cause. Trial comparisons, record NCT02367040-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02367040-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.322 | 0.273 | 0.377 | wilson | |
| Risk in group 2 | 0.342 | 0.27 | 0.423 | wilson | |
| Risk difference, group 1 minus group 2 | -0.02 | -0.114 | 0.0702 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.942 | 0.714 | 1.24 | log | |
| Odds ratio, group 1 over group 2 | 0.914 | 0.602 | 1.39 | log | |
| Number needed to treat, for one fewer death from any cause on Copanlisib + Rituximab than on Placebo + Rituximab | 50 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Copanlisib + Rituximab | Copanlisib (60 mg) was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m\^2) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Copanlisib was administered before rituximab. | 99 | 307 | EG000 |
| Group 2 | Placebo + Rituximab | Placebo was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m\^2) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Placebo was administered before rituximab. | 50 | 146 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Time frame for Serious and Other Adverse Events - from first administration of study drug until 30 days after the last study drug intake. - Time frame for number of death (all causes) - from randomization up to approximately 9 years.
Source ClinicalTrials.gov
Trial
- Title
- Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
- NCT number
- NCT02367040
- Phases
- PHASE3
- Conditions
- Lymphoma,Non-Hodgkin
- Interventions
- Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
- Lead sponsor
- Bayer
- Results first posted
- 2022-01-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02367040?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02367040-deaths